UNSPSC 51292920: Imipramine embonate

This classification denotes a tricyclic antidepressant with the molecular formula C23H16O6.2C19H24N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MC34P30298. European Medicines Agency schedules imipramine embonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02643MIG. The term imipramine embonate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule imipramine embonate under HS 29339990.

SMILES: CN(C)CCCN1C2CCCCC2CCC3C1CCCC3.CN(C)CCCN1C2CCCCC2CCC3C1CCCC3.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O.

UNSPSC 51292920 Imipramine embonate is a Commodity code that represents a specific pharmaceutical product; however, recent state and local procurement activity tagged to this code does not align with the product's nominal scope. The opportunities posted under the code reflect broader pharmaceutical procurement and drug-management services—including naloxone kits, safe drug deactivation systems, generic multi-source pharmaceuticals, and direct-to-manufacturer prescription programs—rather than imipramine embonate specifically. State and local issuers soliciting pharmaceutical products typically include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The scope of work across these opportunities spans emergency-response medications, community health support supplies, and managed pharmacy benefit programs designed to improve prescription fulfillment efficiency and cost control.

Recent activity reflects geographic spread across Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, designed to establish direct state-pharmacy-manufacturer relationships outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 to establish multiple-award contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Vendors responding to pharmaceutical solicitations at this tier typically must maintain relationships with authorized drug wholesalers, comply with FDA manufacturing standards and Drug Supply Chain Security Act requirements, and provide detailed pricing and product documentation with specified national drug codes.